English
Regional settings| Spread | 1.81 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ €5,000.00 Short position overnight fee ~ €4,000.00 | -0.022099% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ €5,000.00 Short position overnight fee ~ €4,000.00 | -0.000123% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | EUR | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | Germany | ||||
| Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 41.47 |
| Open | 41.47 |
| 1-Year Change | -33.32% |
| Day's Range | 38.62 - 41.47 |
Stratec SE is a Germany-based company engaged in the development and manufacture of fully automated systems based on its own patented technologies for its partners in the fields of in-vitro diagnostics and life sciences in Germany and internationally. Its business activities are divided into three segments: Instrumentation, which designs and manufactures fully automated analyzer systems for its clinical diagnostics and biotechnology customers; Diatron, which offers systems, system components, consumables, and tests for the low throughput hematology and clinical chemistry applications, and Consumables, which develops and sells scientific materials, such as nucleic acid purification and designs and produces smart consumables in the fields of diagnostics, life sciences, and medical technology. In addition, the Company develops workflow software for networking various analyzer systems, as well as develops and sells scientific materials and technologies.
BRIEF: For the nine months ended 30 September 2021, StratecSE revenues increased 26% to EUR225.4M. Net income beforeextraordinary items increased 95% to EUR36.3M. Revenuesreflect Instrumentation segment increase of 30% toEUR109.9M, Diatron segment increase of 25% to EUR35.2M. Netincome benefited from General administration expensesdecrease of 19% to EUR12.1M (expense), Research anddevelopment expenses decrease of 30% to EUR5.7M (expense).
07/2006, Scrip Issue, 1.994 new shares for every 1 shareheld.
